An Open-Label Multicenter Randomized Phase 2 Study Evaluating the Safety and Efficacy of Ramucirumab (IMC-1121B) Drug Product or IMC-18F1 Combination with Capecitabine or Capecitabine Monotherapy in Unresectable Locally Advanced or Metastatic Breast C
K
Kathy Miller, MD
Primary Investigator
J
Jessica MacLean
Primary Investigator
Overview
No Description Available
Description
No Description Available
Eligibility
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Breast Cancer
-
Age: Between 18 Years - 100 Years
-
Gender: Female
Updated on
19 Apr 2024.
Study ID: 1011-07
